Johnson & Johnson (JNJ) Offering Possible 16.28% Return Over the Next 10 Calendar Days

Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $130.00 short put and a strike $125.00 long put offers a potential 16.28% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $130.00 by expiration. The full premium credit of $0.70 would be kept by the premium seller. The risk of $4.30 would be incurred if the stock dropped below the $125.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 70.12 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs
Sun, 05 Aug 2018 23:42:02 +0000
NANJING, China—At a cancer conference in Chicago in June last year, a little-known Chinese startup stunned researchers with early results showing its experimental gene therapy was abating an aggressive form of blood cancer in patients back home. Six months later, the startup, Nanjing Legend Biotechnology Co., received $350 million from Johnson & Johnson for the global rights to co-develop and market the experimental treatment. In May, the U.S. Food and Drug Administration approved its testing on Americans, making it the first Chinese-developed gene therapy to receive such a signoff.

The 4 Cheapest ‘Dividend Kings' to Buy Today
Sat, 04 Aug 2018 16:00:00 +0000
In the world of investing, Dividend Kings are the best of the best when it comes to returning cash to shareholders over the long term. You can see the full list of Dividend Kings here. In this article, we'll explore four Dividend Kings that are trading with the largest discounts to fair value today.

Eli Lilly’s Q2 2018 Earnings: New Products
Fri, 03 Aug 2018 11:31:00 +0000
Eli Lilly & Co.’s (LLY) new products portfolio includes several drugs that have been launched since 2014. This portfolio includes Olumiant, Lartruvo, Taltz, Jardiance, Trulicity, Cyramza, Basaglar, and Verzenio. The chart below compares the revenues for LLY’s new products since the first quarter of 2017.

Missouri governments sue drug companies over opioid epidemic
Thu, 02 Aug 2018 20:13:39 +0000
Ten Missouri counties and one city filed suit Wednesday against 49 companies, accusing them of worsening the opioid epidemic by misbranding drugs, among other things. The 274-page lawsuit, filed in St. Louis Circuit Court, seeks damages on behalf of the plaintiffs and their residents. The plaintiffs are Jefferson, Cape Girardeau, Christian, Crawford, Greene, Iron, Jasper, Stone, Taney, and Washington counties, and the city of Joplin.

WHO sees complex vaccine and security questions in Ebola response
Thu, 02 Aug 2018 18:06:32 +0000
It will be complicated and perhaps impossible to use a vaccine to tackle Democratic Republic of Congo's new Ebola outbreak, the World Health Organization's emergency response chief said on Thursday. An Ebola outbreak was declared in northeastern Congo's North Kivu province on Wednesday, and almost 20 WHO officials are already on their way to the epicentre, Peter Salama told Reuters at WHO's headquarters in Geneva. Officials have not yet confirmed which type of Ebola is causing the outbreak.

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.